Atjaunināt sīkdatņu piekrišanu

E-grāmata: Drug Delivery to Tumors: Recent Strategies and Techniques

Edited by , Edited by , Edited by
  • Formāts: PDF+DRM
  • Izdošanas datums: 12-Feb-2025
  • Izdevniecība: Springer Verlag, Singapore
  • Valoda: eng
  • ISBN-13: 9789811989308
Citas grāmatas par šo tēmu:
  • Formāts - PDF+DRM
  • Cena: 142,75 €*
  • * ši ir gala cena, t.i., netiek piemērotas nekādas papildus atlaides
  • Ielikt grozā
  • Pievienot vēlmju sarakstam
  • Šī e-grāmata paredzēta tikai personīgai lietošanai. E-grāmatas nav iespējams atgriezt un nauda par iegādātajām e-grāmatām netiek atmaksāta.
  • Formāts: PDF+DRM
  • Izdošanas datums: 12-Feb-2025
  • Izdevniecība: Springer Verlag, Singapore
  • Valoda: eng
  • ISBN-13: 9789811989308
Citas grāmatas par šo tēmu:

DRM restrictions

  • Kopēšana (kopēt/ievietot):

    nav atļauts

  • Drukāšana:

    nav atļauts

  • Lietošana:

    Digitālo tiesību pārvaldība (Digital Rights Management (DRM))
    Izdevējs ir piegādājis šo grāmatu šifrētā veidā, kas nozīmē, ka jums ir jāinstalē bezmaksas programmatūra, lai to atbloķētu un lasītu. Lai lasītu šo e-grāmatu, jums ir jāizveido Adobe ID. Vairāk informācijas šeit. E-grāmatu var lasīt un lejupielādēt līdz 6 ierīcēm (vienam lietotājam ar vienu un to pašu Adobe ID).

    Nepieciešamā programmatūra
    Lai lasītu šo e-grāmatu mobilajā ierīcē (tālrunī vai planšetdatorā), jums būs jāinstalē šī bezmaksas lietotne: PocketBook Reader (iOS / Android)

    Lai lejupielādētu un lasītu šo e-grāmatu datorā vai Mac datorā, jums ir nepieciešamid Adobe Digital Editions (šī ir bezmaksas lietotne, kas īpaši izstrādāta e-grāmatām. Tā nav tas pats, kas Adobe Reader, kas, iespējams, jau ir jūsu datorā.)

    Jūs nevarat lasīt šo e-grāmatu, izmantojot Amazon Kindle.

This book summarizes emerging drug delivery strategies and new technologies for cancer treatment from the perspective of cancer pathology, including immunotherapy strategies, biomimetic drug delivery strategies, live cell drug delivery strategies, nanocrystal technology and 3D Printing technology, etc. With the development of related fields such as pharmaceutical science, materials science and nanomedicine, drug delivery systems have made significant progress in the treatment of cancer. With the in-depth study of different types of drug delivery systems, clinical transformation will be necessary. Some clinical trials have proved the obvious advantages of drug delivery vehicles in anti-cancer treatment. However, the characterization of nanomaterials, safety issues and production issues limit the application. Importantly, accurate in vitro and in vivo models are needed to predict the therapeutic effect of drug delivery systems in the clinic. The drug delivery system has been continuously innovated and improved in cancer treatment, and has broad application prospects.
Cancer pathology.- Development and advantages of drug delivery systems.- Drug delivery strategies targeting tumor.- Immunotherapy nanocarrier.- Combined therapy.- Prodrug Nanocarrier.- Smart drug delivery vehicle.- Cell-derived / bionic drug delivery vehicle.- Cellular drug delivery vehicle.- Nanocrystal technology.- Drug delivery technology 3D printing.- Microneedle-based transdermal drug delivery technology.
Dr. Lesheng Teng holds an academic appointment of Professor at Jilin University. His research is focused on a highly interdisciplinary combination of nanotechnology, biomaterials, drug delivery, and immunotherapy. He has developed various nanoparticle platforms for delivery of small molecules, proteins, and nucleic acids (e.g., siRNA and mRNA). He has published over 120 peer-reviewed papers and holds over 20 patents/patent applications. Representative papers were published in Nature Biomedical Engineering, Nano Letters, Biotechnology Advances, ACS Applied Materials & Interfaces, Journal of Controlled Release, Theranostics and Nanoscale. He has also received many awards, such as excellent supervisor, and others. Dr. Teng obtained his BS degree and PhD degree from Jilin University.





 





Dr. Zhaogang Yang is an assistant professor in the Department of Radiation Oncology, UT Southwestern Medical Center. Dr. Yang received his B.S. in Pharmaceutical Sciences (2003) and M.S. in Pharmaceutics (2006) from Peking University, China. Then, he completed his M.S. in Pharmacology (2010) and Ph.D. in Pharmaceutical Sciences (2012) at the Ohio State University, USA. He served as a post doctor in Mayo Clinic in Rochester for 1 year (2013), and a research associate at the Ohio State University for 6 years (2013-2019). Dr. Yang's research interests focus on the application of nanotechnology in drug delivery, including novel nanoparticle-based cancer detection, gene delivery and cancer therapy, and nanoelectroporation in gene therapy. He has authored 4 book chapters, more than 80 peer-reviewed journal papers, 7 conference abstracts, and 2 patents. He is a consultant editor of "International Journal of Nanomedicine". In addition, he is the Guest Editor for "Current Organic Chemistry", "Dose-Response " and Molecules special issues.





 





Dr. Chong Li is a professor of the College of Pharmaceutical Sciences in Southwest University (Chongqing, China). He received BS degree from Sichuan University (China) in 2005, earned his Ph.D. degree in pharmacy from Fudan University in 2010. He is on the Young Editorial Boards for the Acta Pharmaceutica Sinica B. Prof. Chong Li has got several awards such as the National Excellent Doctoral Dissertation (2013), Young Pharmaceutical Scientist Award from Chinese Pharmaceutical Association (2015), and the Youth Scholar of Yangtze River (2018). He has published more than 30 papers on J Am Chem Soc, Angew Chem Int Ed, ACS Nano, Nano Lett, Proc Natl Acad Sci USA, etc. His research interests focus on the design of smart drug delivery systems based on natural products and derivatives (functional peptides and small molecules, etc.), and their application in targeted drug delivery, involving antitumor and anti-infection therapy, and the treatment of central nervous system diseases.